Brings over 20 years of commercial and medical expertise in the pharmaceutical industry and the cannabis space
OTTAWA, ON / ACCESSWIRE / September 4, 2020 / Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is excited to announce that Dania Scott has joined Tetra as the Senior Vice President Commercial Strategy. She will be the lead executive responsible for the global commercialization of QIXLEEF™ and will jointly report to the Chief Executive Officer and the Chief Operating Officer.
Prior to joining Tetra Bio-Pharma, Dania worked as Director of Pharmacy at Canopy Growth Corporation where she led the Canadian strategy and tactical plans for Retail & Hospital Pharmacy including pharmacy education, business development, public affairs initiatives, key opinion leaders and key accounts management (2017-2020). Dania worked on the cannabis file at Shoppers Drug Mart (2015-2017) where she led and supported launch initiatives within the cannabis space including pharmacy education, strategy, marketing, and medical cannabis operationalization.
Dania assumed diversified leadership roles within the pharmaceutical industry, in sales management, marketing, and medical functions at companies including GlaxoSmithKline, Procter & Gamble Pharma, Roche and Eisai (1998-2015). She contributed to the growth and launch of several pharmaceutical products in varied therapeutic areas in the MENA (Middle East/North America) region and Canada.
Over the last five years, Dania has developed a unique skill set that includes cannabinoid education, commercialization, and business development within the cannabis space. She led the training of thousands of Canadian pharmacists on all aspects of cannabinoids. This experience combined with her interest in cannabinoid medicine and polypharmacy reduction was a key asset for joining Tetra.
Dr. Guy Chamberland, CEO and CRO commented, “Dania has the experience and skills that Tetra requires to prepare for the commercialization of QIXLEEF™ in Canada, USA, Europe and Central and South America. Earlier this year Tetra completed an overnight financing to accelerate the development of QIXLEEF™. To date, Tetra has delivered on the value driving milestones of launching the Plenitude© clinical trial in the USA, demonstrating in humans the preferential metabolite profile and now the initiation of its global commercial strategy. Dania will work with Tetra’s medical device and cannabis supply partners to bring QIXLEEF™ to these territories.”
“I am extremely excited with the addition of Dania to the Tetra Team. Dania will also commercially support other brands from our diversified product portfolio. Her competencies in pharmaceutical commercial operations are stellar and this will largely benefit our entire portfolio even though her focus will be on QIXLEEF™”, commented Steeve Néron, COO.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX:TBP) (OTCQB:TBPMF), is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a FDA and a Health Canada approved clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Our evidence-based scientific approach has enabled us to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.:
Tetra Bio-Pharma Inc
Dr. Guy Chamberland, M.Sc., Ph.D.
Chief Executive Officer
Phone: + 1 (833) 977-7575
Alpha Bronze, LLC
Mr. Pascal Nigen
Phone: + 1 (646) 255-0433
Ms. Carol Levine APR, FCPRS
Phone: + 1 (416) 425-9143 ext. 226
Mobile: + 1 (514) 703-0256
SOURCE: Tetra Bio-Pharma
View source version on accesswire.com: